Senzo, a Philadelphia, PA-based life sciences firm, raised further $1.9M in Equity funding.
The spherical was led by BioAdvance and Wellness Coaches.
Led by CEO Jeremy Stackawitz, Senzo is an in vitro diagnostics firm creating cellular, point-of-care and self-testing merchandise and gadgets with the flexibility to precisely conduct testing the place healthcare professionals and sufferers want it most.
The firm intends to make use of the funds to finish validation, execute scientific trials, safe FDA EUA authorization, and scale manufacturing for the ALF COVID-19 take a look at, in addition to to advance R&D for brand spanking new Flu A/B, RSV, Tuberculosis, HIV, Hepatitis-C, and Strep exams.
Senzo plans to finish ALF COVID-19 scientific trials and safe FDA EUA regulatory approval in 1H 2023, with exams commercially obtainable in the 2H 2023.